HomeMolecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12) Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Featured Products

E1051 MRTX1133 MRTX1133 is a highly selective inhibitor of mutant KRAS G12D and can reversibly binds to the activated and inactivated KRAS G12D mutants and inhibit their activity. The specificity of MRTX1133 to KRAS G12D is more than 1000 times that of wild-type KRAS.
E1474 BI-2865 BI-2865 is a none-covalent pan-KRAS Inhibitor. It binds to WT, G12C, G12D, G12V and G13D mutant KRAS with KDs of 6.9, 4.5, 32, 26, 4.3 nM respectively and inhibits the proliferation of G12C, G12D or G12V mutant KRAS expressing BaF3 ce
E1549 AZD0095 AZD0095 is a selective and orally active Monocarboxylate transporter 4 (MCT4) inhibitor with IC50 of 1.3 nM and effectively inhibits the tumor growth in NCI-H358 xenografts in combination with Cediranib.
E1858 RMC-7977 RMC-7977 is a potent, reversible, tri-complex oral inhibitor that selectively targets active (GTP-bound) forms of KRAS, HRAS, and NRAS, which exhibits broad-spectrum activity against both mutant and wild-type variants (a RASMULTI (ON) inhibitor). It also exhibits significant anti-tumor efficacy in pancreatic ductal adenocarcinoma (PDAC).
E1908 HRO761 HRO761 is a potent, selective, allosteric inhibitor of Werner syndrome RecQ helicase (WRN). It binds at the interface of the D1 and D2 helicase domains, locking WRN in an inactive conformation, and demonstrates anti-proliferative effects specifically in microsatellite instability (MSI) cancer cells.
S1067 SB431542 SB431542 is a potent and selective inhibitor of ALK5 with IC50 of 94 nM in a cell-free assay, 100-fold more selective for ALK5 than p38 MAPK and other kinases.
S1077 SB202190 SB202190 is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis.
S1105 LY294002 LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
S2619 MG132 MG132 ((S,R,S)-(-)-MG132, Z-Leu-D-Leu-Leu-al) is a potent proteasome (ChTL, TL, and PGPH) inhibitor. MG132 also inhibits calpain (IC50=1.2 μM). MG132 can be used to induce animal models of Parkinson’s disease.
S7085 IWP-2 IWP-2 is an inhibitor of Wnt processing and secretion with IC50 of 27 nM in a cell-free assay, selective blockage of Porcn-mediated Wnt palmitoylation, does not affect Wnt/β-catenin in general and displays no effect against Wnt-stimulated cellular responses. IWP-2 specifically inhibits CK1δ.
S7507 LDN-193189 Dihydrochloride LDN-193189 (DM3189) 2HCl is a selective BMP signaling inhibitor, inhibits the ALK1, ALK2, ALK3 and ALK6 with IC50s of 0.8 nM, 0.8 nM, 5.3 nM and 16.7 nM in the kinase assay, respectively. LDN-193189 inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50s of 5 nM and 30 nM in C2C12 cells, respectively, exhibits 200-fold selectivity for BMP versus TGF-β.
S7609 GW4869 GW4869 (GW69A, GW554869A) is a neutral, noncompetitive inhibitor of sphingomyelinase (SMase) with an IC50 of 1 μM. It is selective for N-SMase, and does not inhibit acid SMase at up to at least 150 μM, also is a commonly used exosome inhibitor.
S7692 A-83-01 A-83-01 is a potent inhibitor of TGF-β type I receptor (ALK5-TD) with IC50 of 12 nM. A-83-01 also inhibits the transcription induced by activin/nodal type I receptor (ALK4-TD) and nodal type I receptor (ALK7-TD) with IC50 of 45 nM and 7.5 nM, respectively.Solutions are unstable and should be fresh-prepared.
S7803 Gsk484 Hydrochloride GSK484 HCl, a benzoimidazole derivative, is a selective and reversible inhibitor of peptidylarginine deiminase 4 (PAD4) with IC50 of 50 nM in the absence of Calcium.
S7809 MCC950 Sodium MCC950 Sodium is a potent, selective inhibitor of NLRP3 with IC50 of 7.5 nM in BMDMs; but not the AIM2, NLRC4 or NLRP1 inflammasomes.
S8383 S63845 S63845 is a new, selective MCL-1 inhibitor with the Kd value of 0.19 nM and has no discernible binding to the other BCL-2 members, BCL-2 or BCL-XL.
S8740 A-485 A-485 is a potent, selective and drug-like p300/CBP catalytic inhibitor with an IC50 of 0.06 μM for p300 HAT. It is selective over BET bromodomain proteins and >150 non-epigenetic targets.
S8843 AZD7648 AZD7648 is a potent inhibitor of DNA-PK with an IC50 of 0.6 nM in biochemical assay and more than 100-fold selective against 396 other kinases.
S8874 PLX5622 PLX5622 is a highly selective CSF-1R inhibitor (IC50 < 10 nmol/L), showing > 20-fold selectivity over KIT and FLT3.
S9870 STM2457 STM2457 is a highly potent and selective first-in-class catalytic inhibitor of RNA Methyltransferase METTL3 with an IC50 of 16.9 nM. STM2457 is highly specific for METTL3 and showed no inhibition of other RNA methyltransferases.

New Products Click to View More

E6646 BMS-986260 BMS-986260 is an orally active immuno-oncology agent that inhibits TGFβR1 with an IC50 of 1.6 nM. It shows selectivity for TGFβR1 compared to TGFβR2 and over 200 other kinases. In MINK and NHLF cell lines, BMS-986260 blocks TGFβ-induced pSMAD2/3 nuclear translocation with IC50 values of 350 nM and 190 nM, respectively.
E6638 VS-7375 (GFH375) VS-7375 (GFH375) is an oral small-molecule inhibitor that selectively targets KRAS G12D in both its active (GTP-bound) and inactive (GDP-bound) forms. This dual-state inhibition results in stronger tumor suppression compared to single-state inhibitors. It exhibits potent anti-proliferative and anti-tumor effects in KRAS G12D-mutant models, including an intracranial GP2D tumor model.
E6517 PKN1 PKN1/2-IN-1 is a cell-permeable compound that inhibits PKN1 and PKN2, with IC50 values of 16 nM and 210 nM, and Ki values of 8 nM and 108 nM, respectively. In NanoBRET assays, it shows intracellular PKN2 binding with an IC50 of 2.1 μM. This compound is applicable for investigating tumor cell migration and related physiological processes.
E6521 HRS‑5346 Lp(a)-IN-5 (Compound A) is an orally administered lipoprotein(a) (Lp(a)) inhibitor. This compound demonstrates inhibition of Apo(a) and ApoB protein assembly with an IC50 of 0.41 nM. It may be useful for studying diseases associated with increased plasma Lp(a) levels, including cardiovascular disorders.
E6578 AS1708727 AS1708727 is an orally bioavailable Foxo1 inhibitor that exhibits EC50 values of 0.33 μM against G6Pase and 0.59 μM against PEPCK.
E6498 Atebimetinib (IMM-1-104) Atebimetinib inhibits MEK tyrosine kinase and demonstrates antineoplastic effects.
E6639 Auceliciclib (AU3-14,Ulecaciclib ) Ulecaciclib is an orally active cyclin-dependent kinase (CDK) inhibitor with Ki values of 0.62 μM for CDK2/Cyclin A, 0.2 nM for CDK4/Cyclin D1, 3 nM for CDK6/Cyclin D3, and 0.63 μM for CDK7/Cyclin H. This compound demonstrates blood-brain barrier penetration and favorable pharmacokinetic properties.
P1231 Mazdutide (IBI362, LY330567) Mazdutide (IBI-362; LY-3305677) is a synthetic long-acting oxyntomodulin analog that functions as a dual agonist of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). The compound exhibits binding affinity for human and mouse GCGR (Ki values of 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki values of 28.6 nM and 25.1 nM, respectively). In mouse islets, mazdutide stimulates insulin secretion with an EC50 of 5.2 nM. This agent has been investigated in research related to obesity and type 2 diabetes (T2D).
E6643 SS-3091 SS-3091 is a pan-KRas inhibitor that targets the interaction interfaces of KRas. By destabilizing the ARaf/KRas complex, it modulates downstream signaling pathways. This compound exhibits activity against KRas G12D, G12C, G12V, and G12S mutants in multiple cancer cell lines.
E5927 Mito-LND (Mito-Lonidamine) Mito-LND (Mito-Lonidamine) is an orally administered mitochondria-targeted compound that inhibits oxidative phosphorylation (OXPHOS). This agent reduces mitochondrial bioenergetics, promotes reactive oxygen species generation, and triggers autophagic cell death in lung cancer cells.
E6511 ADT-1004 ADT-1004 is a RAS inhibitor that may be investigated for Ras-mediated diseases.
P1262 Eloralintide (LY-3841136) Eloralintide (LY 3841136) is an AMYR agonist with potential applications in type 2 diabetes and obesity research.
E6526 MCB-294 MCB-294 is a pan-KRAS inhibitor that targets both active (GTP-bound) and inactive (GDP-bound) KRAS states, exhibiting Kd values of about 1 pM and 10 nM, respectively. It shows preferential inhibition of KRAS over NRAS and HRAS. The compound inhibits proliferation of hTERT-HPNE cells harboring G12D, G12C, G12V, G12S, G13D, and wild-type KRAS variants, with IC50 values around 700 nM. MCB-294 triggers apoptosis in KRAS-mutated tumors and demonstrates activity against KRASG12C inhibitor-resistant cancer cells while modulating the tumor immune microenvironment. This compound serves as a research tool for pancreatic, colorectal, and lung cancer investigations.
E6411 RP03707 RP03707 is a PROTAC molecule designed to degrade KRASG12D, consisting of three components: a KRASG12D inhibitor (, red), a linker (black), and an E3 ligase ligand (blue).
E5936 FT895 FT895 inhibits HDAC11 with an IC50 of 3 nM.
E6647 Bireociclib (XZP-3287,CDK4/6-IN-2) CDK4/6-IN-2 is a CDK4 and CDK6 inhibitor obtained from patent US20180000819A1 (Compound 1). It exhibits IC50 values of 2.7 nM for CDK4 and 16 nM for CDK6.
E6653 AR-C118925XX AR-C118925XX is a P2Y2 receptor antagonist. It reduces ATP-induced IL-6 production and p38 phosphorylation. In mice, AR-C118925XX attenuates Bleomycin -induced dermal fibrosis. Additionally, it suppresses ATP-stimulated tumor growth.
E6651 HGC652 HGC652 functions as a molecular glue by targeting E3 ubiquitin ligase TRIM21. It facilitates the formation of a TRIM21-NUP98 ternary complex, leading to degradation of NUP155 and nuclear pore complex proteins, ultimately resulting in cell death. The compound shows inhibitory effects on the proliferation of various cancer cell lines, with activity dependent on TRIM21 expression levels.
E6636 DY268 DY268 is a farnesoid X receptor (FXR) antagonist with an IC50 of 7.5 nM. In cellular assays, it inhibits FXR transactivation with an IC50 of 468 nM. This compound has applications in drug-induced liver injury (DILI) research.
E6634 Thiethylperazine Thiethylperazine is a phenothiazine derivative that acts as an oral dopamine D2-receptor and histamine H1-receptor antagonist. This compound functions as an ABCC1 activator and has been shown to decrease amyloid-β (Aβ) accumulation in mice. It exhibits anti-emetic, antipsychotic, and antimicrobial properties.